Vascular Effects of Hesperidin in Metabolic Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-11-30

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It has been suggested that cardiovascular risk factors either independently or in cluster (metabolic syndrome) increase the risk of both type 2 diabetes (DM2) and cardiovascular diseases (CVD). Consumption of citrus fruits is linked to reduced cardiovascular morbidity and mortality. Hesperidin is a flavanone abundant in citrus fruit with putative vasodilator actions in vitro. While molecular mechanisms of vascular actions of hesperidin begin to be explored, no data on in vivo vascular effect of this flavanone has been ever acquired.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Orange Juice, Hesperidin and Their Role in Vascular Health Benefit

NCT04731987

Metabolic Syndrome Vascular Compliance Predisposition to Cardiovascular Disease

COMPLETED NA

Effects of Hesperidin on Insulin Sensitivity

NCT01773486

Obesity Insulin Resistance

WITHDRAWN PHASE2

Study of the Bioavailability of Three Hesperidin Extracts.

NCT03984916

Biological Availability

COMPLETED NA

Bioavailability of Hesperidine and Narirutin From Orange Juice to Identify Metabotypes in Hypertension

NCT04234100

Blood Pressure Hypertension

COMPLETED NA

Effect of Orange Juice on Glycemic Response

NCT03522896

Effect of Food on Postprandial Hyperglycemia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endothelial Dysfunction Metabolic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hesperidin, 500 mg per day

500 mg daily of oral Hesperidin for 3 weeks

Group Type ACTIVE_COMPARATOR

Hesperidin

Intervention Type DRUG

Administration of oral Hesperidin, 500 mg/daily

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administration of oral Placebo, 500 mg/daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hesperidin

Administration of oral Hesperidin, 500 mg/daily

Intervention Type DRUG

Placebo

Administration of oral Placebo, 500 mg/daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Metabolic Syndrome (ATPIII criteria)
* BMI \<35
* Age 20-55

Exclusion Criteria

* History of cancer.
* History of cardiovascular diseases.
* Any other acute or chronic illness which requires administration of steroids or other drugs able to interfere with glucose or lipid metabolism.

Minimum Eligible Age

20 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No